Pengpeng Zhang

机构：Tianjin Medical University Cancer Institute and Hospital, Nanjing Medical University · ORCID：0009-0004-6951-2634

发表论文 20 篇 · 总被引 402 次 · h-index 10

代表论文

• The microbiome in cancer (2025 · iMeta · 被引 69)
• Mitochondrial Pathway Signature (MitoPS) predicts immunotherapy response and reveals NDUFB10 as a key immune regulator in lung adenocarcinoma (2025 · Journal for ImmunoTherapy of Cancer · 被引 59)
• Bridging Chronic Inflammation and Digestive Cancer: The Critical Role of Innate Lymphoid Cells in Tumor Microenvironments (2024 · International Journal of Biological Sciences · 被引 37)
• Autoantibody detection to tumor-associated antigens of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn, and Koc for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma (2013 · Diseases of the Esophagus · 被引 37)
• Clinical prognostication and immunotherapy response prediction in esophageal squamous cell carcinoma using the DNA damage repair‐associated signature (2024 · Environmental Toxicology · 被引 30)
• A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment (2016 · Scientific Reports · 被引 30)